Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
NSCLC patients with metastatic disease who have failed at least one prior treatment and have
a minimum of two metastatic lesions (at least one measurable), are eligible if they have an
ECOG Performance Status of 0-1. Patients will receive on Day 1, ipilimumab (every 6 weeks)
concurrently with radiation (6Gy x 5 fractions). Nivolumab (every 2 weeks) will be given in
addition to ipilimumab on day 22.